Naproxol 750 represents a significant case study within the metabolic pharmacy realm . The mechanism of action fundamentally targets cyclooxygenase catalysts , specifically both COX isoforms, diminishing the production of inflammatory mediators . Given a biochemical perspective , Relafen's efficacy copyrights on its ability to preferentially inhibi